# Anvumetostat Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol) (MTAPESTRY 104).

> **NCT06333951** · PHASE1 · RECRUITING · sponsor: **Amgen** · enrollment: 500 (estimated)

## Conditions studied

- Thoracic Tumors
- Non-small Cell Lung Cancer

## Interventions

- **DRUG:** Anvumetostat
- **DRUG:** Carboplatin
- **DRUG:** Paclitaxel
- **DRUG:** Pembrolizumab
- **DRUG:** Pemetrexed
- **DRUG:** Sotorasib

## Key facts

- **NCT ID:** NCT06333951
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-09-17
- **Primary completion:** 2028-10-27
- **Final completion:** 2031-10-27
- **Target enrollment:** 500 (ESTIMATED)
- **Last updated:** 2026-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06333951

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06333951, "Anvumetostat Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol) (MTAPESTRY 104).". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06333951. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*